Adjuvant Quisinostat in High-Risk Uveal Melanoma

This trial is studying a drug called quisinostat as an additional (adjuvant) treatment after primary therapy for uveal melanoma — a rare type of eye cancer — in patients considered high-risk for the cancer coming back. Quisinostat works by blocking enzymes that help cancer cells survive. **You may be eligible if...** - You have been diagnosed with uveal melanoma (melanoma of the eye) - Your cancer is considered high-risk — meaning it has features likely to spread - You have completed your primary eye treatment (such as radiation or surgery) - You are an adult in adequate overall health **You may NOT be eligible if...** - Your cancer has already spread to other parts of the body (distant metastases) - You have serious heart rhythm abnormalities (QT prolongation) - You have significant liver or kidney problems - You are pregnant or breastfeeding - You have uncontrolled infections or other serious illnesses Talk to your doctor to see if this trial is right for you.